Lead Discovery and covalent screening

Jason Pembroke, Group Leader - Bioanalytical at Domainex, presents Lead Discovery and covalent screening. Covalent inhibitors continue to be an area of interest due to their high potency, long duration of action, and reduced dosing frequency leading to improved patient compliance. However, their irreversible nature makes off target effects a critical concern. Domainex presented its mass-spectrometry-driven covalent screening platform, built around a library of more than 700 covalent fragments.